Lipoprotein

There are 744 papers on lipoprotein in aging research: 98 trials and 354 observational studies in people, 3 in animals, 3 in cells, 267 reviews.

Biomarker

744 papers study it5,266 more mention it621 findings

MeSH

691 new papers in 30 daysSee all 6,010 papers on lipoprotein

“Percent change in OxPL-apo(a) correlated more closely than OxPL-apoB with percent change in Lp(a) than did OxPL-apoB.”
Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a)Journal of the American College of Cardiology2026doi:10.1016/j.jacc.2026.07.015
  • Human trial98
  • Humans354
  • Animals3
  • Cells3
  • In silico4

Interventions

70

Pelacarsen

downin humans12downin reviews1−99% to −80%

13 studies
  1. Pelacarsen decreases lipoprotein in humans (86% placebo-adjusted reduction; between-group GMR 0.14 (95% CI 0.11–0.18)).

    “GMR between groups (pelacarsen/placebo) was 0.14 (95% CI: 0.11, 0.18; P<0.0001), equivalent to an 86% placebo-adjusted reduction.”

    Human trialUS Black/African American and Hispanic participants with elevated lipoprotein(a) and established atherosclerotic cardiovascular disease80 mg monthly52 weeksn = 422

    Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study

    Circulation. Population health and outcomes

  2. Pelacarsen decreases lipoprotein in humans (Preexisting cardiovascular disease and lipoprotein(a) of at least 70 mg per deciliter) (64.4 versus 233.4 nmol per liter with placebo at 12 months).

    “At 12 months, the lipoprotein(a) level was 64.4 nmol per liter in the pelacarsen group and 233.4 nmol per liter in the placebo group.”

    Human trialPreexisting cardiovascular disease and lipoprotein(a) of at least 70 mg per deciliterantisense oligonucleotideserum80 mg monthly12 months27.0% womensn = 8,322

    Pelacarsen did not lower major cardiovascular event risk

    The New England journal of medicine

  3. Pelacarsen decreases lipoprotein in humans (-72% (95% CI: -79%, -61%; P < .0001)).

    “The placebo-adjusted Lp(a) change from baseline at week 52 was -72% (95% CI: -79%, -61%; P < .0001).”

    Human trialinjection80 mg52 weeks

    Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial

    European heart journal

  4. Pelacarsen decreases lipoprotein in humans (MD -54.15 percentage points, 95% CI -76.75 to -31.55).

    “pelacarsen (MD - 54.15, 95% CI -76.75 to -31.55)”

    Review

    Comparative efficacy and safety of PCSK9-directed therapies, RNA-based lipid therapies, and muvalaplin for lipoprotein(a) lowering: a systematic review and network meta-analysis

    Frontiers in endocrinology

  5. Pelacarsen decreases lipoprotein in humans (compared with placebo) (−29.0 mg/dL at 20 mg Q4W to −66.0 mg/dL at 60 mg Q4W).

    “Pelacarsen reductions ranged from –29.0 mg/dL (20 mg Q4W) to –66.0 mg/dL (60 mg Q4W).”

    Reviewcompared with placeboantisense oligonucleotide20–60 mg Q4W

    Comparative Efficacy of Nucleic Acid-Based Therapies Targeting Lipoprotein(a): A Network Meta-Analysis

    AHA Scientific Sessions 2026 abstract

  6. Pelacarsen decreases lipoprotein in humans (patients with established cardiovascular disease in Lp(a)HORIZON; topline results only).

    “Topline results announced in September 2026 indicated that pelacarsen lowered Lp(a) but did not reduce the primary composite cardiovascular endpoint in patients with established cardiovascular disease.”

    Reviewpatients with established cardiovascular disease in Lp(a)HORIZON; topline results onlyhepatocyte-directed antisense oligonucleotide

    Pelacarsen and Lp(a)HORIZON: Interpreting the Disconnect Between Lipoprotein(a) Lowering and Cardiovascular Outcomes

    The American journal of medicine

  7. Pelacarsen decreases lipoprotein in humans (sponsor-reported Lp(a)HORIZON topline data; complete peer-reviewed results unavailable).

    “pelacarsen lowered Lp(a) but did not significantly reduce the prespecified primary cardiovascular endpoint in the overall Lp(a)HORIZON population”

    Reviewsponsor-reported Lp(a)HORIZON topline data; complete peer-reviewed results unavailable

    Lipoprotein(a) After Myocardial Infarction: Residual Risk, Measurement, and the Unresolved Therapeutic Question

    Biomedicines

  8. Pelacarsen decreases lipoprotein in humans (up to 99%).

    “demonstrated Lp(a) reductions of up to 99%”

    Review

    Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention

    Methodist DeBakey cardiovascular journal

  9. Pelacarsen decreases lipoprotein in humans (up to 80-95% reductions).

    “Emerging Lp(a)-specific therapies, including pelacarsen, olpasiran, muvalaplin, and SLN360, demonstrate up to 80-95% reductions in Lp(a)”

    Review

    Lipoprotein(a) in Japan: An Expert Consensus Statement

    Journal of atherosclerosis and thrombosis

  10. Pelacarsen decreases lipoprotein in humans (Up to 80% reduction).

    “Antisense oligonucleotide therapy with pelacarsen reduced Lp(a) levels by up to 80%”

    Reviewplasma

    Efficacy and tolerability of targeted lipoprotein(a)-lowering therapies: A systematic review

    Journal of clinical lipidology

All 13

More on Pelacarsen

Olpasiran

downin humans9

9 studies
  1. Olpasiran decreases lipoprotein in humans (network meta-analysis versus placebo) (MD −87.72%; 95% CI −113.78 to −61.66).

    “Compared to placebo, olpasiran showed the largest reduction in Lp(a) (MD: –87.72%; 95% CI: –113.78 to –61.66)”

    Human trialnetwork meta-analysis versus placebosmall interfering RNAn = 1,185

    Olpasiran Outperforms Other Subcutaneous Lipoprotein(a)-Lowering Agents in Efficacy and Safety: A Network Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2025 abstract

  2. Olpasiran decreases lipoprotein in patients with ASCVD and elevated Lp(a).

    “In patients with ASCVD and elevated Lp(a), olpasiran reduces Lp(a) irrespective of apo(a) isoform size”

    Human trialin patients with ASCVD and elevated Lp(a)36 weeks

    Efficacy of Olpasiran by Apolipoprotein(a) Isoform Size: Insights from the OCEAN(a)-DOSE Trial

    AHA Scientific Sessions 2025 abstract

  3. Olpasiran decreases lipoprotein in humans (versus placebo) (MD -98.34 nmol/L (95% CI -102.75 to -93.92)).

    “Olpasiran demonstrated a significant reduction in Lp(a) levels compared to placebo (MD: -98.34 nmol/L, 95% CI: [-102.75; -93.92], p < 0.0001)”

    Human trialversus placebo

    SAT-260 Comparative Efficacy of Olpasiran and Zerlasiran in Reducing Lipoprotein(a) Levels: A Network Meta-Analysis of Clinical Trials

    ENDO 2025 abstract

  4. Olpasiran decreases lipoprotein in humans (MD -92.06 percentage points, 95% CI -107.91 to -76.21).

    “Among Lp(a)-targeted therapies, substantial percentage-point differences were observed with olpasiran (MD -92.06, 95% CI -107.91 to -76.21)”

    Review

    Comparative efficacy and safety of PCSK9-directed therapies, RNA-based lipid therapies, and muvalaplin for lipoprotein(a) lowering: a systematic review and network meta-analysis

    Frontiers in endocrinology

  5. Olpasiran decreases lipoprotein in humans (Compared with control in pooled randomized controlled trials) (MD −93.48%; 95% CI −110.55 to −76.42).

    “The greatest reductions were observed with olpasiran (MD, –93.48%; 95% CI, –110.55 to –76.42)”

    ReviewCompared with control in pooled randomized controlled trials

    Comparative Effects of Lipoprotein(a)-Targeted and Lipid-Modifying Therapies on Percent Change in Lipoprotein(a)

    AHA Scientific Sessions 2026 abstract

  6. Olpasiran decreases lipoprotein in humans (compared with placebo) (MD −100.5 mg/dL, 95% CI −105.5 to −95.5).

    “The largest reductions were observed with olpasiran 225 mg (MD –100.5 mg/dL, 95% CI –105.5 to –95.5)”

    Reviewcompared with placebosiRNA225 mg

    Comparative Efficacy of Nucleic Acid-Based Therapies Targeting Lipoprotein(a): A Network Meta-Analysis

    AHA Scientific Sessions 2026 abstract

  7. Olpasiran decreases lipoprotein in humans (> 95% reduction).

    “olpasiran (> 95% reduction, OCEAN(a)-Outcomes)”

    Reviewsmall interfering RNA

    Novel Lipoprotein (a) Therapies: A Comprehensive Review

    Current atherosclerosis reports

  8. Olpasiran decreases lipoprotein in humans (percentage Lp(a) change versus placebo) (mean difference -92.06% (95% CI -109.80 to -74.32) versus placebo).

    “Compared with placebo, Olpasiran was the most effective therapy for both percentage [mean difference: -92.06, 95% (-109.80; -74.32), P-score: 0.94] and absolute reductions”

    Reviewpercentage Lp(a) change versus placebo

    Efficacy and safety of lipoprotein(a)-targeted therapeutics: a systematic review and network meta-analysis

    Frontiers in cardiovascular medicine

  9. Olpasiran decreases lipoprotein in the OCEAN(a)-DOSE trial, in patients with established ASCVD and Lp(a) > 150 nmol/L (greater than 95% reduction).

    “demonstrated greater than 95% reduction in Lp(a)”

    Reviewin the OCEAN(a)-DOSE trial, in patients with established ASCVD and Lp(a) > 150 nmol/Lsmall interfering RNA (siRNA)

    Lowering of Lipoprotein(a) with Olpasiran

    Cardiovascular & hematological disorders drug targets

More on Olpasiran

Levocarnitine

downin humans5no changein humans2

6 studies
  1. Levocarnitine decreases lipoprotein in humans (mixed hyperlipidemia and elevated Lp(a) concentration) (-19.4% (p = 0.01; p = 0.016 vs placebo/simvastatin)).

    “Lp(a) was significantly reduced in the L-carnitine/simvastatin group [-19.4%, from 52 (20-171) to 42 (15-102) mg/dL; p = 0.01]”

    Human trialmixed hyperlipidemia and elevated Lp(a) concentration2 g/day L-carnitine plus 20 mg/day simvastatin12 weeksn = 29

    L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study

    Lipids

  2. Levocarnitine showed no clear effect on lipoprotein in humans (hemodialysis patients with Lp (a) hyperlipoproteinemia).

    “There were no significant differences between the two groups in mean changes of serum interleukin-1β, tumor necrosis factor-α, Lp (a), and oxidized low-density lipoprotein concentrations.”

    Human trialhemodialysis patients with Lp (a) hyperlipoproteinemiaoralserum1000 mg/d12 weeksn = 36

    Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia

    Hemodialysis international. International Symposium on Home Hemodialysis

  3. Levocarnitine decreases lipoprotein in humans (co-administered with simvastatin, compared with simvastatin alone).

    “Lp(a) serum levels increase from baseline to 60 days in the simvastatin group alone versus a significant decrease in the combination group.”

    Human trialco-administered with simvastatin, compared with simvastatin alone2 g/day60 days

    Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus

    Atherosclerosis

  4. Levocarnitine decreases lipoprotein in humans (versus placebo at 6 months) (P < 0.05 vs placebo).

    “We observed a significant improvement after 6 months (P < 0.05) in the Lp(a) value in patients taking L-carnitine compared with those taking placebo.”

    Human trialversus placebo at 6 months1-g oral tablet1 g twice daily6 monthsn = 94

    The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus

    Clinical therapeutics

  5. Levocarnitine decreases lipoprotein in humans (hyper Lp(a)) (-11.7% vs placebo treatment).

    “L-carnitine (2 g/day) significantly reduced Lp(a) levels (-7.7% vs baseline and -11.7% vs placebo treatment)”

    Human trialhyper Lp(a)2 g/day

    L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a)

    Nutrition, metabolism, and cardiovascular diseases : NMCD

  6. Levocarnitine showed no clear effect on lipoprotein in humans (intravenous administration) (WMD: -2.91 mg/dL, 95% CI: -10.22, 4.41, p = 0.436).

    “but not intravenous L-carnitine (WMD: -2.91 mg/dL, 95% CI: -10.22, 4.41, p = 0.436).”

    Reviewintravenous administration

    Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials

    Scientific reports

  7. Levocarnitine decreases lipoprotein in humans (all RCTs) (WMD: -8.82 mg/dL, 95% CI: -10.09, -7.55, p < 0.001).

    “The meta-analysis showed a significant reduction of Lp(a) levels following L-carnitine supplementation (WMD: -8.82 mg/dL, 95% CI: -10.09, -7.55, p < 0.001).”

    Reviewall RCTs

    Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials

    Scientific reports

More on Levocarnitine

Muvalaplin

downin humans5downin silico1−86% to −65%

6 studies
  1. Muvalaplin decreases lipoprotein in humans (MD -61.49 percentage points, 95% CI -80.26 to -42.72).

    “muvalaplin (MD -61.49, 95% CI -80.26 to -42.72)”

    Review

    Comparative efficacy and safety of PCSK9-directed therapies, RNA-based lipid therapies, and muvalaplin for lipoprotein(a) lowering: a systematic review and network meta-analysis

    Frontiers in endocrinology

  2. Muvalaplin decreases lipoprotein in silico (Population PK/PD simulations using Phase 1 and Phase 2 data) (Model-predicted reduction of up to 86%).

    “Simulations of percent change from baseline for Lp(a) suggested a model predicted reduction of up to 86% with increasing dose levels”

    In silicoPopulation PK/PD simulations using Phase 1 and Phase 2 data10 mg to 240 mg

    Once-Daily Oral Muvalaplin Achieves Significant Lp(a) Lowering: Insights from Population PKPD Modelling Across Phase 1 and Phase 2

    AHA Scientific Sessions 2026 abstract

  3. Muvalaplin decreases lipoprotein in humans (Phase 2 testing).

    “An oral small molecule, muvalaplin, achieved comparable reductions in phase 2 testing.”

    ReviewPhase 2 testing

    RNA-Based Therapies for Lipoprotein(a) Reduction: Antisense Oligonucleotides, Small Interfering RNAs, and Emerging Platforms

    Current atherosclerosis reports

  4. Muvalaplin decreases lipoprotein in humans (early-phase studies).

    “muvalaplin, an oral small-molecule inhibitor targeting Lp(a) assembly, has shown promising reductions in Lp(a) levels in early-phase studies.”

    Reviewearly-phase studiesplasma

    Efficacy and tolerability of targeted lipoprotein(a)-lowering therapies: A systematic review

    Journal of clinical lipidology

  5. Muvalaplin decreases lipoprotein in humans (up to 85.8%).

    “reduces intact Lp(a) by up to 85.8% in phase 2 KRAKEN trials”

    Revieworal small-molecule

    Novel Lipoprotein (a) Therapies: A Comprehensive Review

    Current atherosclerosis reports

  6. Muvalaplin decreases lipoprotein in humans (up to 65%).

    “In Phase I trials, daily administration of muvalaplin for 14 days reduced Lp(a) levels by up to 65%.”

    Review14 days

    Muvalaplin: A Novel Oral Therapy for Targeted Reduction of Plasma Lipoprotein(a)

    Cardiovascular & hematological disorders drug targets

More on Muvalaplin

Inclisiran

downin humans5−33% to −18%

5 studies
  1. Inclisiran decreases lipoprotein in humans (added to statin therapy) (27% reduction (70 to 51 mg/dL)).

    “and Lp(a) reduction of 27% (baseline 70 ± 15 → 51 ± 12 mg/dL, p<0.001)”

    Human trialadded to statin therapy300 mg subcutaneously at baseline, 3 months, then every 6 months24 monthsn = 172

    Inclisiran in combination with statin therapy achieves profound LDL-C and lipoprotein(a) reduction without acute cardiovascular events in high-risk patients with familial hypercholesterolemia

    ESC Congress 2026 abstract

  2. Inclisiran decreases lipoprotein in humans (elevated LDL-C, low/moderate ASCVD risk, monotherapy) (-30.27%).

    “inclisiran induced a significant (P < 0.0001) reduction in other atherogenic lipoproteins and lipid biomarkers (placebo-adjusted LSM difference: lipoprotein(a), -30.27%”

    Human trialelevated LDL-C, low/moderate ASCVD risk, monotherapy150 daysn = 207

    Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial

    Journal of clinical lipidology

  3. Inclisiran decreases lipoprotein in humans (dyslipidemia and atherosclerotic plaques in peripheral arteries) (-33%).

    “and Lp(a) by 33%”

    Human trialdyslipidemia and atherosclerotic plaques in peripheral arteries90 daysn = 22

    Inclisiran Therapy and Lipid Profile Dynamics in Real-World Clinical Practice in Russia: Interim Results of an Observational Study

    Kardiologiia

  4. Inclisiran is linked with lower lipoprotein in humans (unadjusted analyses) (-8% to -17%).

    “and from -8% to -17% with inclisiran”

    Humansunadjusted analyses

    Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study

    Atherosclerosis

  5. Inclisiran decreases lipoprotein in humans (meta-analyses of RCTs) (18.00%).

    “and inclisiran (18.00%; high certainty).”

    Reviewmeta-analyses of RCTs

    Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials

    Drugs

More on Inclisiran

Antisense oligonucleotides

downin humans5−90%

5 studies
  1. Antisense oligonucleotides decrease lipoprotein in humans (Elevated Lp(a); ASO trials versus placebo) (−74 to −80 nmol/L).

    “ASO trials demonstrated more modest reductions (−74 to −80 nmol/L) with greater variability.”

    ReviewElevated Lp(a); ASO trials versus placebo

    RNA targeted therapies for lipoprotein(a) lowering: systematic review and meta analysis of siRNA and antisense oligonucleotides

    ESC Congress 2026 abstract

  2. Antisense oligonucleotides decrease lipoprotein in humans (65% to >95%).

    “RNA-targeted agents, comprising antisense oligonucleotides and small interfering RNAs, together with a first oral small-molecule inhibitor, lower Lp(a) by about 65% to more than 95%”

    Review

    Lipoprotein(a) in the statin era: from risk marker to therapeutic target

    Frontiers in pharmacology

  3. Antisense oligonucleotides decrease lipoprotein in humans (up to 90%).

    “Novel therapies-including antisense oligonucleotides, siRNA therapeutics, CETP inhibitors, and experimental gene-editing approaches-show promising potential, reducing Lp(a) levels by up to 90%.”

    Review

    Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives

    Biomedicines

  4. Antisense oligonucleotides decrease lipoprotein in humans (Phase II trials).

    “antisense oligonucleotides and small interfering RNAs) and a small molecule inhibitor of Lp(a) synthesis, demonstrated substantial and often durable Lp(a)-lowering effects in Phase II trials.”

    ReviewPhase II trials

    Lipoprotein(a)-lowering therapies: a promising future

    European heart journal

  5. Antisense oligonucleotides decrease lipoprotein in humans.

    “Novel therapeutics, including antisense oligonucleotides, small interfering RNAs, and small molecular inhibitors, have shown promising Lp(a)-lowering effects”

    Review

    A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions

    Journal of lipid and atherosclerosis

More on Antisense oligonucleotides

PCSK9 inhibitors

downin humans2downin reviews2

4 studies
  1. PCSK9 inhibitors are linked with lower lipoprotein in humans (-15.3%, -16.7%, -19.0% at 3, 9 and 21 months).

    “PCSK9i therapy resulted in a significant and sustained reduction in lipoprotein(a), with mean changes of -15.3%, -16.7%, and -19.0% at 3, 9, and 21 months, respectively (all p < 0.001).”

    Humans21 monthsn = 1,112

    Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study

    Atherosclerosis

  2. PCSK9 inhibitors decrease lipoprotein (20%-30% reduction).

    “PCSK9 inhibitors (eg, alirocumab, evolocumab, and tafolecimab) not only reduced low-density lipoprotein (LDL-C) by 55%-60% but also lowered Lp(a) by 20%-30%.”

    Review

    Therapeutic Effects of PCSK9 Inhibitors on Lp(a)-Associated Atherosclerosis: Evidence and Perspectives

    Journal of cardiovascular pharmacology

  3. PCSK9 inhibitors decrease lipoprotein in humans (15-20% reduction, smaller than effect on LDL-C).

    “PCSK9 inhibitors have been found to reduce Lp(a) levels but to a lesser extent than their effect on LDL-C”

    Review

    Lowering of Lipoprotein(a) with Olpasiran

    Cardiovascular & hematological disorders drug targets

  4. PCSK9 inhibitors decrease lipoprotein.

    “reducing the lipoprotein concentration and slowing thrombosis”

    Review

    PCSK9 Inhibition: From Current Advances to Evolving Future

    Cells

More on PCSK9 inhibitors

RNA-targeted therapies

downin humans3

3 studies
  1. RNA-targeted therapies decrease lipoprotein in humans (Elevated Lp(a) (≥125 nmol/L or ≥50 mg/dL); compared with placebo) (−86.6 nmol/L (95% CI −98.5 to −74.7); 82–95% relative suppression).

    “Across all RNA-targeted therapies, pooled analysis demonstrated a mean absolute Lp(a) reduction of −86.6 nmol/L (95% CI −98.5 to −74.7; I2=99%)”

    ReviewElevated Lp(a) (≥125 nmol/L or ≥50 mg/dL); compared with placebon = 8,799

    RNA targeted therapies for lipoprotein(a) lowering: systematic review and meta analysis of siRNA and antisense oligonucleotides

    ESC Congress 2026 abstract

  2. RNA-targeted therapies decrease lipoprotein in humans (phase 2 randomized trials) (80-95% or more).

    “RNA-targeted therapies - antisense oligonucleotides and small interfering RNA agents - and an oral inhibitor of Lp(a) particle assembly have produced pharmacodynamic Lp(a) reductions of 80-95% or more in phase 2 randomized trials.”

    Reviewphase 2 randomized trials

    Targeting Lipoprotein(a) in Cardiovascular Disease: Emerging Therapies and Clinical Implications

    Journal of cardiovascular pharmacology

  3. RNA-targeted therapies decrease lipoprotein in humans (80-95% reductions).

    “novel RNA-targeted therapies achieve unprecedented 80-95% reductions”

    Review

    The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice

    Reviews in cardiovascular medicine

More on RNA-targeted therapies

Coenzyme Q10

downin humans3

3 studies
  1. Coenzyme Q10 decreases lipoprotein in humans.

    “serum levels of lipoprotein(a) reduced significantly in the carnitine, coenzyme Q10, and combination groups”

    Human trialcompared with baseline and with placebo at 3 months in statin-treated hemodialysis patients3 months

    Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy

    Iranian journal of kidney diseases

  2. Coenzyme Q10 decreases lipoprotein in humans (acute coronary disease with moderately raised lipoprotein(a)) (31.0% reduction versus 8.2% with placebo; net reduction 22.6%).

    “Serum lipoprotein(a) showed significant reduction in the coenzyme Q10 group compared with the placebo group”

    Human trialacute coronary disease with moderately raised lipoprotein(a)hydrosoluble Q-Gel60 mg twice daily28 days

    Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role

    International journal of cardiology

  3. Coenzyme Q10 decreases lipoprotein in humans (WMD: -3.54 mg/dL, 95% CI: -5.50, -1.58).

    “Overall, CoQ10 supplementation was paralleled by a slight but significant reduction of plasma Lp(a) levels (WMD: -3.54 mg/dL, 95% CI: -5.50, -1.58; p<0.001)”

    Reviewn = 409

    Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis

    Pharmacological research

More on Coenzyme Q10

Growth hormone

upin humans3

3 studies
  1. Growth hormone increases lipoprotein in humans (abdominal obesity; compared with placebo).

    “Serum lipoprotein(a) [Lp(a)] concentration increased (P<0.05 vs. placebo).”

    Human trialabdominal obesity; compared with placebo9 monthsmalesn = 30

    A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

  2. Growth hormone increases lipoprotein in humans (treatment of GH-deficient adults and girls with Turner syndrome) (119 +/- 35% in GH-deficient adults; 126 +/- 44% in girls with Turner syndrome).

    “We conclude that long-term GH treatment increases and IGF-I decreases circulating levels of Lp(a).”

    Human trialtreatment of GH-deficient adults and girls with Turner syndrome6-9 months

    Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)

    European journal of endocrinology

  3. Growth hormone increases lipoprotein in hypopituitary adults (P < 0.05).

    “During 12 months of GH therapy, a significant increase in serum lipoprotein-(a) was observed (P < 0.05).”

    Human trialin hypopituitary adultsrecombinant humanmean 0.2 IU/kg.week12 monthsn = 22

    The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults

    The Journal of clinical endocrinology and metabolism

More on Growth hormone

Acetylcysteine

no changein humans2downin humans1

2 studies
  1. Acetylcysteine showed no clear effect on lipoprotein in humans.

    “There was no significant effect on plasma Lp(a) levels.”

    Human trialn = 11

    N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels

    Atherosclerosis

  2. Acetylcysteine decreases lipoprotein in subjects with high plasma level of Lp(a) (-7% (P = 0.02)).

    “a small but significant decrease in Lp(a) concentration of 7% (P = 0.02) was observed after administration of NAC in a dose of 1.2 g d-1 for 6 weeks”

    Human trialin subjects with high plasma level of Lp(a)1.2 g d-16 weeksn = 12

    N-acetylcysteine and serum concentrations of lipoprotein(a)

    Journal of internal medicine

  3. Acetylcysteine showed no clear effect on lipoprotein in subjects with median Lp(a) 14.3 mg dl-1.

    “plasma level of Lp(a) was not changed by administration of NAC 1.2 g d-1 for 4 weeks in 7 subjects”

    Human trialin subjects with median Lp(a) 14.3 mg dl-11.2 g d-14 weeksn = 7

    N-acetylcysteine and serum concentrations of lipoprotein(a)

    Journal of internal medicine

More on Acetylcysteine

Enlicitide

downin humans2

2 studies
  1. Enlicitide decreases lipoprotein in humans (placebo-corrected; effect shown for baseline Lp(a) ≥125 nmol/L) (absolute -45.8 nmol/L (95% CI -52.6, -39.2) at baseline ≥125 nmol/L; -8.4 nmol/L below 125 nmol/L).

    “Placebo-corrected %Lp(a) reduction with enlicitide was significant across all baseline Lp(a) levels (p<0.001 for all)”

    Human trialplacebo-corrected; effect shown for baseline Lp(a) ≥125 nmol/L20 mg24 weeksn = 3,187

    An oral drug lowers lipoprotein(a) across patient groups

    ESC Congress 2026 abstract

  2. Enlicitide decreases lipoprotein in humans (placebo-controlled, week 24).

    “the percent change in lipoprotein(a) levels at week 24 were significantly greater with enlicitide than with placebo”

    Reviewplacebo-controlled, week 2420 mg daily24 weeks

    A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

    The New England journal of medicine

More on Enlicitide

Alirocumab

downin humans2

2 studies
  1. Alirocumab decreases lipoprotein in humans (recent acute coronary syndromes) (mean 25% reduction in time-weighted Lp(a)).

    “Alirocumab reduced time-weighted Lp(a) by a mean 25%.”

    Human trialrecent acute coronary syndromes

    Association of lipoprotein(a) levels with risk of serious bleeding : findings from the ODYSSEY OUTCOMES trial

    ESC Congress 2026 abstract

  2. Alirocumab decreases lipoprotein in humans (meta-analyses of RCTs) (18.55-26.46%).

    “alirocumab (18.55-26.46%; high certainty), and inclisiran (18.00%; high certainty).”

    Reviewmeta-analyses of RCTs150 mg biweekly

    Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials

    Drugs

More on Alirocumab

Curcumin

downin humans2

2 studies
  1. Curcumin decreases lipoprotein in type 2 diabetic patients with mild to moderate CAD (P = 0.043).

    “Nano-curcumin significantly mitigated the hs-CRP and LipoPr (a) levels following 90 days of treatment”

    Human trialin type 2 diabetic patients with mild to moderate CAD80 mg/day90 daysn = 64

    Three months of combination therapy with nano-curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double-blinded, placebo-controlled clinical trial

    BioFactors (Oxford, England)

  2. Curcumin decreases lipoprotein in humans (dietary supplementation with highly bioavailable forms) (SMD -0.96, 95% CI -1.82 to -0.11).

    “dietary supplementation with highly bioavailable forms of curcumin significantly reduces Lp(a) levels [Standardized Mean Difference (SMD)= -0.96 (95 % Confidence Interval (CI): -1.82, -0.11)].”

    Reviewdietary supplementation with highly bioavailable forms

    The effect of highly bioavailable forms of curcumin on lipoprotein(a) plasma levels: A systematic review and meta-analysis of randomized clinical studies

    Prostaglandins & other lipid mediators

More on Curcumin

HRS-5632

downin humans1

1 study
  1. HRS-5632 decreases lipoprotein in humans (Healthy participants with lipoprotein(a) ≥75 nmol/L) (≥90% reduction at ≥10 mg; at week 48, ≥90% reduction in 87.5% and 100.0% of the 200 mg and 400 mg cohorts, respectively).

    “HRS-5632 at 10 mg or higher could reduce lipoprotein(a) by ≥90%.”

    Human trialHealthy participants with lipoprotein(a) ≥75 nmol/L10 mg or higherapproximately one year at 200 mg or 400 mgn = 40

    Safety, Tolerability, and Lipoprotein(a)-Lowering Effect of HRS-5632, an Extended Long-Acting Small Interfering RNA Targeting Lipoprotein(a): A Randomized, Double-Blind, First-in-Human Study

    AHA Scientific Sessions 2026 abstract

More on HRS-5632

All 70

Effects

55

Mortality

no changein humans5HR 0.63–1.04

5 studies
  1. Lipoprotein was not clearly linked with mortality in humans (HR 1.04, 95% CI 0.84–1.28; p = 0.734).

    “The multivariable adjusted Cox regression confirmed the absence of a significant association between Lp(a) concentrations and total mortality”

    HumansHistory of hospitalized acute myocardial infarction; high lipoprotein(a) (≥ 50 mg/dL) versus low (< 50 mg/dL)Median follow-up: 18.2 yearsn = 617

    Plasma lipoprotein (a) and long-term all-cause mortality in myocardial infarction survivors: a cohort study

    Lipids in health and disease

  2. Lipoprotein was not clearly linked with mortality in humans (Elevated versus nonelevated Lp(a), with LDL-C <70 mg/dL on statin and/or ezetimibe therapy).

    “Stroke/TIA and all-cause mortality did not differ between groups.”

    HumansElevated versus nonelevated Lp(a), with LDL-C <70 mg/dL on statin and/or ezetimibe therapyLp(a) ≥50 mg/dL or ≥125 nmol/LMedian follow-up of 2.6 to 3.1 years42.3% femalesn = 41,750

    Lipoprotein(a) and Residual Vascular Risk Among Patients Achieving Optimal LDL-C: A Real-World Cohort Analysis

    AHA Scientific Sessions 2026 abstract

  3. Lipoprotein was not clearly linked with mortality in humans (Black adults; elevated versus normal lipoprotein(a)) (RR 0.835; p=0.213).

    “not associated with 3-point major adverse cardiovascular events (RR 0.978, p=0.856), myocardial infarction (RR 1.250, p=0.202), all-cause mortality (RR 0.835, p=0.213)”

    HumansBlack adults; elevated versus normal lipoprotein(a)1 year

    Elevated Lipoprotein(a) and Incident Peripheral Artery Disease in Black Adults: A Propensity-Matched Real-World Analysis

    AHA Scientific Sessions 2026 abstract

  4. Lipoprotein was not clearly linked with mortality in patients with established ASCVD (HR 0.63, 95% CI: 0.38-1.06, p = 0.78).

    “10-year all-cause mortality (HR 0.63, 95% CI: 0.38-1.06, p = 0.78).”

    Humansin patients with established ASCVD10-yearn = 798

    Lipoprotein(a), Atherosclerotic Plaque Burden, and Long-term Cardiovascular Outcomes in Patients With Coronary Artery Disease

    European journal of preventive cardiology

  5. Lipoprotein was not clearly linked with mortality in humans (acute decompensated heart failure without hypertension) (P ≥ 0.41).

    “However, there were no associations between mortality and Lp(a) in those without hypertension (P ≥ 0.41).”

    Humansacute decompensated heart failure without hypertension4.1 years (median)

    Impact of hypertension on associations of all-cause mortality with admission lipoprotein (a) in acute decompensated heart failure

    International journal of cardiology. Cardiovascular risk and prevention

Venous thromboembolism

no changein humans2no changein reviews1HR 0.99

3 studies
  1. Lipoprotein was not clearly linked with venous thromboembolism in humans (High versus low lipoprotein(a) concentrations in Black and White individuals).

    “Elevated Lp(a) was not associated with venous thromboembolism in either group”

    HumansHigh versus low lipoprotein(a) concentrations in Black and White individuals

    Cardiovascular Risk Associated with High vs Low Lipoprotein(a) Across Black and White Individuals

    AHA Scientific Sessions 2026 abstract

  2. Lipoprotein showed no clear effect on venous thromboembolism in humans (Cohort studies) (HR 0.99, 95% CI 0.85–1.15).

    “cohort studies showed no association (HR 0.99 [0.85-1.15]; I2 = 0%)”

    ReviewCohort studies

    Association between elevated lipoprotein (a) and venous thromboembolism: A systematic review and meta-analysis

    Atherosclerosis

  3. Lipoprotein showed no clear effect on venous thromboembolism (genetic association studies).

    “genetic association studies have not demonstrated an association between high plasma levels of Lp(a) and the risk of venous thromboembolism”

    Reviewgenetic association studies

    Lipoprotein(a), platelet function and cardiovascular disease

    Nature reviews. Cardiology

More on Venous thromboembolism

Stroke

no changein humans3OR 0.97

3 studies
  1. Lipoprotein was not clearly linked with stroke in humans (OR 0.97, 95% CI 0.86-1.09).

    “not with stroke/TIA (OR 0.97, 95% CI 0.86-1.09)”

    Humansn = 23,654

    Distribution of lipoprotein(a) and its association with atherosclerotic cardiovascular disease in a large real-world Polish cohort

    Journal of clinical lipidology

  2. Lipoprotein was not clearly linked with stroke in humans (elevated Lp(a) >= 125 nmol/L) (HR 0.95, 95% CI 0.75-1.20).

    “but not stroke (HR 0.95, 95% CI 0.75-1.20; P = 0.649).”

    Humanselevated Lp(a) >= 125 nmol/L

    Integrating Lipoprotein(a) with Retinal Imaging Biomarkers for Cardiovascular Risk Assessment: UK Biobank Analysis

    ADA Scientific Sessions 2026 abstract

  3. Lipoprotein was not clearly linked with stroke in humans.

    “but not with stroke”

    Humans

    Cross-Sectional Association of Lipoprotein(a) Levels With Vascular Complications and Related Parameters in a Japanese Type 2 Diabetes Cohort

    Journal of atherosclerosis and thrombosis

More on Stroke

Major adverse cardiovascular events

no changein humans2

2 studies
  1. Lipoprotein was not clearly linked with major adverse cardiovascular events in humans following the commencement of a statin in CAD patients (adjusted hazard ratio = 1.29, 95% CI = 0.52-3.18, P = .586).

    “a percent change in Lp(a) levels of ≥20% following the commencement of a statin was not associated with a greater risk of subsequent MACE”

    Humansfollowing the commencement of a statin in CAD patients65.1 monthsn = 100

    A ≥20% increase in circulating Lp(a) after the commencement of statins, and subsequent risks of atherosclerotic cardiovascular diseases in patients with coronary artery disease

    Journal of clinical lipidology

  2. Lipoprotein was not clearly linked with major adverse cardiovascular events in humans (established ASCVD) (aHR 1.02 (95% CI 0.98-1.06) per 10 mg/dl increment).

    “there was no significant association between Lp(a) and MACE risk (aHR: 1.02 [0.98-1.06] per 10 mg/dl increment, P = 0.341”

    Humansestablished ASCVDn = 2,333

    Residual atherosclerotic risk in older patients with atherosclerotic cardiovascular disease: where inflammation meets lipoprotein(a)

    Age and ageing

Inflammation

upin humans1upin reviews1

2 studies
  1. Lipoprotein increases inflammation.

    “Lp(a) contributes to endothelial dysfunction, promotes vascular inflammation and enhances lipid retention and oxidation within the arterial wall.”

    Reviewarterial wall

    Presumed Mechanisms Underlying Lipoprotein(a)-caused Atherosclerosis

    European cardiology

  2. Lipoprotein induces inflammation in humans.

    “Evidence is accumulating that Lp(a) can exacerbate pathophysiological processes in CAVD, specifically, endothelial dysfunction, formation of foam cells, and promotion of a pro-inflammatory state.”

    Review

    Lipoprotein(a): Expanding our knowledge of aortic valve narrowing

    Trends in cardiovascular medicine

More on Inflammation

Coronary artery disease

no changein humans2HR 1.3

2 studies
  1. Lipoprotein was not clearly linked with coronary artery disease in humans (Lebanese adult tertiary-care cohort).

    “Logistic regression analysis showed no significant association between Lp(a) levels and cardiovascular factors including dyslipidemia, hypertension, coronary artery disease, previous coronary artery bypass graft, and previous myocardial infarction.”

    HumansLebanese adult tertiary-care cohortn = 456

    Distribution of Lipoprotein(a) Levels and Clinical Associations in a Lebanese Adult Population: A Retrospective Observational Study

    Journal of clinical medicine

  2. Lipoprotein was not clearly linked with coronary artery disease in humans (elevated Lp(a) without MetS compared to normal Lp(a) without MetS) (HR: 1.30; 95% CI: 0.94, 1.80).

    “those with elevated Lp(a) without MetS (group 2) did not have increased risk of CHD (HR: 1.30; 95% CI: 0.94, 1.80).”

    Humanselevated Lp(a) without MetS compared to normal Lp(a) without MetS

    Lipoprotein(a) and Metabolic Syndrome are Associated with Increased Risk of Coronary Heart Disease

    AHA Scientific Sessions 2025 abstract

More on Coronary artery disease

Circulating coagulation proteins

no changein humans1

1 study
  1. Lipoprotein was not clearly linked with circulating coagulation proteins in humans After multiple testing correction.

    “After multiple testing correction, genetically predicted lipoprotein(a) had no significant association with any coagulation proteins.”

    HumansAfter multiple testing correction

    Genetically predicted lipoprotein(a), first and recurrent venous thromboembolism, and coagulation proteins: evidence against causal relationships

    Journal of thrombosis and thrombolysis

More on Circulating coagulation proteins

Recurrent venous thromboembolism

no changein humans1HR 1.03

1 study
  1. Lipoprotein was not clearly linked with recurrent venous thromboembolism in humans (Per genetically predicted 100 nmol/L increase) (HR 1.03, 95% CI 0.91–1.16).

    “There was no association with recurrent VTE (hazard ratio 1.03, 95% CI 0.91–1.16, P = 0.68).”

    HumansPer genetically predicted 100 nmol/L increasen = 1,775

    Genetically predicted lipoprotein(a), first and recurrent venous thromboembolism, and coagulation proteins: evidence against causal relationships

    Journal of thrombosis and thrombolysis

More on Recurrent venous thromboembolism

Adverse offspring health outcomes

no changein humans1

1 study
  1. Lipoprotein was not clearly linked with adverse offspring health outcomes in humans (genetically predicted low lipoprotein(a); summary-level analyses).

    “In summary-level analyses, no significant adverse associations of genetically predicted low lipoprotein(a) with reproductive and offspring health outcomes were detected.”

    Humansgenetically predicted low lipoprotein(a); summary-level analyses

    Genetic insights into lipoprotein(a) lowering and reproductive and offspring health outcomes

    European heart journal open

Adverse reproductive health outcomes

no changein humans1

1 study
  1. Lipoprotein was not clearly linked with adverse reproductive health outcomes in humans (genetically predicted low lipoprotein(a); summary-level analyses).

    “In summary-level analyses, no significant adverse associations of genetically predicted low lipoprotein(a) with reproductive and offspring health outcomes were detected.”

    Humansgenetically predicted low lipoprotein(a); summary-level analysesfemales

    Genetic insights into lipoprotein(a) lowering and reproductive and offspring health outcomes

    European heart journal open

Urine albumin

downin humans1

1 study
  1. Lipoprotein decreases urine albumin in humans (predominantly African American elderly cohort with CKD and high Lp(a)) (y = -0.028x).

    “UA however had a clear negative correlation with Lp(a), y = -0.028x.”

    Human trialpredominantly African American elderly cohort with CKD and high Lp(a)n = 44

    2-PUB: Lipoprotein(a) and Kidney Failure Appear to Be Interlinked in an Elderly African American Population at Risk of CVD

    Diabetes

More on Urine albumin

Estimated glomerular filtration rate

downin humans1

1 study
  1. Lipoprotein decreases estimated glomerular filtration rate in humans (predominantly African American elderly cohort with CKD and high Lp(a)) (y = -0.029x).

    “Lp(a) had a negative correlation with eGFR, y = -0.029x.”

    Human trialpredominantly African American elderly cohort with CKD and high Lp(a)n = 44

    2-PUB: Lipoprotein(a) and Kidney Failure Appear to Be Interlinked in an Elderly African American Population at Risk of CVD

    Diabetes

More on Estimated glomerular filtration rate

All 55

Upstream

8

Menopause

upin humans1

1 study
  1. Menopause is linked with higher lipoprotein in women with intermediate baseline Lp(a) (75-125 nmol/L) (median increase of 34.9 nmol/L).

    “those who transitioned through menopause experienced a median increase of 34.9 nmol/L, approximately fourfold greater than women who remained pre- or postmenopausal”

    Humansin women with intermediate baseline Lp(a) (75-125 nmol/L)median 4 yearsfemales

    Menopause linked to crossing a heart disease risk threshold

    European journal of preventive cardiology

Pregnancy

upin humans1

1 study
  1. Pregnancy increases lipoprotein in humans during pregnancy (nearly doubling between weeks 10 and 35).

    “During pregnancy, Lp(a) levels rise substantially, nearly doubling between weeks 10 and 35.”

    Reviewduring pregnancybetween weeks 10 and 35

    Elevated lipoprotein(a) and adverse pregnancy outcomes

    Annals of medicine and surgery (2012)

Traditional cardiovascular risk factors

no changein humans1

1 study
  1. traditional cardiovascular risk factors were not clearly linked with lipoprotein in humans.

    “Lp(a) levels were similar across traditional cardiovascular risk factors categories.”

    Humansn = 388

    Lipoprotein(a) and acute coronary syndrome: Associations with sex, age and traditional cardiovascular risk factors

    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology

menopause

upin humans1RR 2.26

1 study
  1. menopause is linked with higher lipoprotein in humans (women with intermediate visit 1 Lp(a) levels (75-125 nmol/L)) (RR 2.26 (95% CI: 1.31, 3.90)).

    “56% of women with intermediate visit 1 Lp(a) levels who transitioned through menopause between visits had incident Lp(a) [≥]125 nmol/L at visit 2, compared with 29% and 28% of women who remained pre- or postmenopausal, representing an age-adjusted risk ratio of 2.26 (95% CI: 1.31, 3.90).”

    Humanswomen with intermediate visit 1 Lp(a) levels (75-125 nmol/L)median 4 yearsfemales

    Heterogeneity in Lipoprotein(a) Profile Changes Across the Menopausal Transition

    medRxivPreprint

Hormonal transition

upin humans1

1 study
  1. Hormonal transition increases lipoprotein in humans (hormonal transition).

    “Hormonal transition influences the lipid profile by elevating markers such as lipoprotein (a), thereby increasing thrombotic risk.”

    Reviewhormonal transitionfemales

    Cardiometabolic health in women: differences compared to men

    Gaceta medica de Mexico

suPAR

no changein humans1

1 study
  1. suPAR was not clearly linked with lipoprotein in humans (Spearman rho = 0.008; p = 0.60).

    “suPAR and Lp(a) were not correlated (Spearman’s rho = 0.008; p = 0.60).”

    Humansn = 4,357

    Soluble Urokinase Plasminogen Activator Receptor (suPAR), Lipoprotein(a), and Cardiovascular Outcomes in the Multi-Ethnic Study of Atherosclerosis (MESA)

    AHA Scientific Sessions 2025 abstract

More on suPAR

Premenopausal status

no changein humans1

1 study
  1. Premenopausal status showed no clear effect on lipoprotein in humans (Premenopausal versus postmenopausal women in four age-matched studies) (WMD -1.22 mg/dl (95% CI -3.15 to 0.72)).

    “Four studies included pre- and postmenopausal women, matched for age, and these found no difference in Lp(a) concentrations between groups”

    ReviewPremenopausal versus postmenopausal women in four age-matched studiesfemales

    The effect of menopause on lipoprotein (a) concentrations: A systematic review and meta-analysis

    Maturitas

PCSK9

upin humans1

1 study
  1. PCSK9 is linked with higher lipoprotein in humans across PCSK9 tertiles; HeFH group only, not controls.

    “the Lp(a) concentration and percentage of Lp(a)≥300mg/L were increased by PCSK9 tertiles in HeFH group (both p<0.05)”

    Humansacross PCSK9 tertiles; HeFH group only, not controlsPCSK9 tertilesn = 255

    Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study

    Metabolism: clinical and experimental

More on PCSK9

Associations

222

Atherosclerotic cardiovascular disease

upin humans39upin reviews4mixedin humans1HR 1.12–1.44

44 studies
  1. Lipoprotein is associated with atherosclerotic cardiovascular disease in humans (Primary prevention cohort; high lipoprotein(a)) (Incidence increase per 50 mg/dL higher lipoprotein(a): 2.7 per 1000 person-years (95% CI 2.2-3.2) at ages 70-79; 4.5 (3.7-5.4) at ages 80-100).

    “individuals aged 70-100 with high lipoprotein(a) had the highest absolute risk of atherosclerotic cardiovascular disease.”

    HumansPrimary prevention cohort; high lipoprotein(a)Median follow-up 12.5 yearsn = 18,322

    Lipoprotein(a) and Cardiovascular Disease in Individuals Aged 70-100 Years

    AHA Scientific Sessions 2026 abstract

  2. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (CVD-free participants; one-sample Mendelian randomization) (HR per SD 1.05, 95% CI 1.02–1.08).

    “The instrument predicted both outcomes (HR per SD genetically predicted Lp(a) 1.05 [95%CI 1.02-1.08] for ASCVD; 1.12 [1.03-1.23] for AVS)”

    HumansCVD-free participants; one-sample Mendelian randomizationper SD genetically predicted Lp(a)n = 28,949

    Genetic analysis links a blood fat particle to 60 proteins

    AHA Scientific Sessions 2026 abstract

  3. Lipoprotein is associated with atherosclerotic cardiovascular disease in humans (prior ASCVD diagnosis before admission, multivariable analysis) (OR 1.638; 95% CI 1.115–2.405).

    “elevated Lp(a) was independently associated with prior ASCVD (OR 1.638; 95% CI 1.115–2.405; p = 0.012)”

    Humansprior ASCVD diagnosis before admission, multivariable analysisn = 729

    Lipoprotein(a) levels in patients hospitalized for acute coronary syndrome according to prior statin therapy

    ESC Congress 2026 abstract

  4. Lipoprotein is associated with atherosclerotic cardiovascular disease in humans (RERI 0.60; 95% CI 0.10–1.10).

    “Additive interaction was observed for older age (RERI 0.60; 95% CI: 0.10–1.10)”

    HumansAdditive interaction between elevated lipoprotein(a) and older age; without ASCVD at baseline>105 versus ≤105 nmol/LUp to 16 yearsn = 19,495

    Excess atherosclerotic cardiovascular burden associated with elevated lipoprotein(a) across age, sex, and cardiometabolic risk factors: insights from 16-year follow-up of the HUNT Study

    ESC Congress 2026 abstract

  5. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (primary prevention cohort) (HR 1.12 to 1.18 per 50 mg/dL).

    “Hazard ratios per 50 mg/dL higher lipoprotein(a) were similar across all age groups and sexes, ranging from 1.12 to 1.18”

    Humansprimary prevention cohort

    Lipoprotein(a) and Atherosclerotic Cardiovascular Disease Among Adults Aged 20 to 100 Years

    Circulation

  6. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (HR 1.23 (95% CI 1.19-1.27)).

    “highest quintile of TyG, hs-CRP, and Lp(a) was associated with higher ASCVD risk, with hazard ratios (HRs) of 1.32 (95% CI 1.27-1.38), 1.36 (1.30-1.43), and 1.23 (1.19-1.27)”

    Humansn = 320,506

    Metabolic, inflammatory, and lipoprotein(a)-related risk profiling for incident ASCVD: a multi-biomarker study

    Frontiers in endocrinology

  7. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (OR 1.15, 95% CI 1.07-1.24).

    “ln(Lp(a) + 1) was independently associated with the ASCVD (OR 1.15, 95% CI 1.07-1.24)”

    Humansn = 23,654

    Distribution of lipoprotein(a) and its association with atherosclerotic cardiovascular disease in a large real-world Polish cohort

    Journal of clinical lipidology

  8. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (>50 vs ≤50 mg/dL) (AHR 1.36, 95% CI 1.13-1.64).

    “When dichotomized (>50 vs ≤50 mg/dL), Lp(a) was associated with ASCVD in adults aged 40 years or older (AHR range, 1.36; 95% CI, 1.13-1.64)”

    Humans>50 vs ≤50 mg/dL21.3 years

    Traditional and Emerging Lipid Markers for Cardiovascular Risk Assessment in Young vs Older Adults

    JAMA network open

  9. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (HR: 1.24; 95% CI: 1.09-1.41).

    “Lp(a) >50 mg/dL (HR: 1.24; 95% CI: 1.09-1.41) and CAC >0 (HR: 2.44; 95% CI: 2.14-2.77) were independently associated with ASCVD risk”

    Humansn = 11,319

    Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study

    Journal of the American College of Cardiology

  10. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (Per 10 nmol/L genetically predicted lipoprotein(a), assessed by Mendelian randomization) (2% higher risk per 10 nmol/L genetically predicted Lp(a)).

    “MR showed a 2% higher ASCVD risk per 10 nmol/L genetically predicted Lp(a) (P<2×10−16).”

    HumansPer 10 nmol/L genetically predicted lipoprotein(a), assessed by Mendelian randomization

    Linear and Nonlinear Associations Between Lipoprotein(a) and the Risks of Atherosclerotic Cardiovascular Disease

    Circulation journal : official journal of the Japanese Circulation Society

All 45

More on Atherosclerotic cardiovascular disease

Coronary artery disease

upin humans20upin reviews3downin humans1OR 1.012–1.31

24 studies
  1. Lipoprotein is associated with coronary artery disease in humans (Per genetically predicted 100 nmol/L increase) (OR 1.31, 95% CI 1.29–1.33).

    “genetically predicted lipoprotein(a) was strongly associated with increased risk of coronary artery disease (OR 1.31, 95% CI 1.29–1.33)”

    HumansPer genetically predicted 100 nmol/L increasen = 181,522

    Genetically predicted lipoprotein(a), first and recurrent venous thromboembolism, and coagulation proteins: evidence against causal relationships

    Journal of thrombosis and thrombolysis

  2. Lipoprotein predicts coronary artery disease in humans (aHR 1.42, 95% CI 1.15-1.74).

    “FDRs whose index participant had Lp(a) in the highest decile had higher CAD risk”

    HumansIndex participant lipoprotein(a) in the highest decile versus bottom half; incident disease in first-degree relatives13.9 years median follow-up

    Index Lipoprotein(a) and Polygenic Risk Score Identify Coronary Artery Disease Risk in First-Degree Relatives

    AHA Scientific Sessions 2026 abstract

  3. Lipoprotein is associated with coronary artery disease in humans (Approximate OR per doubling 1.07, 95% CrI 1.06–1.08).

    “Overall, Lp(a) was associated with increased risk of CAD (approximate OR per doubling of Lp(a) 1.07, 95% CrI 1.06 - 1.08).”

    HumansPer doubling of genetically inferred Lp(a)n = 657,692

    A blood particle’s heart disease link is similar across ancestries

    AHA Scientific Sessions 2026 abstract

  4. Lipoprotein is linked with a higher risk of coronary artery disease in humans (Inverse-variance weighted Mendelian randomization) (IVW OR 1.15, 95% CI 1.13–1.17).

    “Mendelian randomization confirmed causal effects on PAD (IVW OR=1.05, 95% CI 1.04-1.07) and CAD (IVW OR=1.15, 95% CI 1.13-1.17)”

    HumansInverse-variance weighted Mendelian randomization60% femalesn = 378,834

    Blood particle linked to differing artery disease risks

    AHA Scientific Sessions 2026 abstract

  5. Lipoprotein is associated with coronary artery disease in humans (Hypercholesterolemia; elevated lipoprotein(a) versus non-elevated lipoprotein(a)) (7.4% vs 6.1%; HR 1.20, 95% CI 1.10–1.32).

    “new coronary artery disease (7.4% vs 6.1%; RR 1.21, 95% CI 1.10-1.32; HR 1.20, 95% CI 1.10-1.32; P<0.001)”

    HumansHypercholesterolemia; elevated lipoprotein(a) versus non-elevated lipoprotein(a)1,095 daysn = 15,925

    Elevated Lipoprotein(a) and Cardiovascular Outcomes in Adults with Hypercholesterolemia: A Comparative Observational Study

    AHA Scientific Sessions 2026 abstract

  6. Lipoprotein is linked with a higher risk of coronary artery disease in humans (OR 1.21, 95% CI 1.12-1.32).

    “CAD (OR 1.21, 95% CI 1.12-1.32)”

    Humansn = 23,654

    Distribution of lipoprotein(a) and its association with atherosclerotic cardiovascular disease in a large real-world Polish cohort

    Journal of clinical lipidology

  7. Lipoprotein is associated with coronary artery disease in humans.

    “Higher Lp(a) grades were associated with the prevalence of coronary artery disease (CAD)”

    Humans

    Cross-Sectional Association of Lipoprotein(a) Levels With Vascular Complications and Related Parameters in a Japanese Type 2 Diabetes Cohort

    Journal of atherosclerosis and thrombosis

  8. Lipoprotein is associated with coronary artery disease in humans (history of coronary artery disease).

    “Elevated Lp(a) was associated with a history of coronary artery disease (p-trend=0.003) and with treatment with high-intensity statins alone (p-trend=0.032) or in combination with ezetimibe (p-trend=0.014).”

    Humanshistory of coronary artery diseasen = 388

    Lipoprotein(a) and acute coronary syndrome: Associations with sex, age and traditional cardiovascular risk factors

    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology

  9. Lipoprotein is linked with a higher risk of coronary artery disease in humans (biomarker elevation) (HR 1.20 (95% CI: 1.12-1.29)).

    “1.20 (95% CI: 1.12-1.29) for Lp(a)”

    Humansbiomarker elevation12 yearsn = 215,695

    Combining Genomics With Lipid and Inflammatory Biomarkers to Predict Coronary Artery Disease Risk: UK Biobank Study

    Journal of the American College of Cardiology

  10. Lipoprotein is linked with a lower risk of coronary artery disease in humans (Lp(a) < 50 mg/dL and IL-6 < median) (HR 0.65, 95% CI 0.56-0.74).

    “IL-6 levels below the median and Lp(a) concentrations below 50 mg/dL were also independently and additively associated with lower CHD risk”

    HumansLp(a) < 50 mg/dL and IL-6 < mediann = 408,687

    Genetic variants lowering lipoprotein(a) and downregulating interleukin-6 signalling are additively associated with a decreased risk of cardiovascular disease

    European journal of preventive cardiology

All 25

More on Coronary artery disease

Cardiovascular disease

upin humans11HR 1.16–2.07

11 studies
  1. Lipoprotein is linked with a higher risk of cardiovascular disease in humans (baseline MASLD and elevated Lp(a)) (HR 2.07, 95% CI: 1.39-3.09).

    “individuals with baseline MASLD and elevated Lp(a) were independently associated with an increased risk of hard cardiovascular disease (HR 2.07, 95% CI: 1.39-3.09)”

    Humansbaseline MASLD and elevated Lp(a)

    The association of MASLD, lipoprotein(a) and long-term outcomes: Results from the multi-ethnic study of atherosclerosis

    Metabolism: clinical and experimental

  2. Lipoprotein is linked with a higher risk of cardiovascular disease in humans (elevated Lp(a) >= 125 nmol/L) (10.8% vs 9.0%; HR 1.16, 95% CI 1.06-1.26).

    “Elevated Lp(a) was associated with higher risk of any incident CVD event (10.8% vs 9.0%; HR 1.16, 95% CI 1.06-1.26; P <0.001)”

    Humanselevated Lp(a) >= 125 nmol/L

    Integrating Lipoprotein(a) with Retinal Imaging Biomarkers for Cardiovascular Risk Assessment: UK Biobank Analysis

    ADA Scientific Sessions 2026 abstract

  3. Lipoprotein is linked with a higher risk of cardiovascular disease in humans (primary prevention) (aHR 1.08 (95% CI, 1.06-1.09)).

    “Per 1-SD increase, aHRs were 1.08 (95% CI, 1.06-1.09) for log-Lp(a)”

    Humansprimary prevention14.6 years median follow-upn = 328,031

    Lipoprotein(a), Insulin Resistance, and Cardiovascular Disease in the UK Biobank

    Journal of the American Heart Association

  4. Lipoprotein is associated with cardiovascular disease in humans (independent of LDL cholesterol concentrations and other traditional risk factors).

    “high lipoprotein(a) remains a genetically determined risk modifier of cardiovascular disease independently of LDL cholesterol concentrations and other traditional risk factors.”

    Reviewindependent of LDL cholesterol concentrations and other traditional risk factors

    The Clinical Relevance of Lipoprotein(a) in the Post-Lp(a)HORIZON Era: A Statement of the European Atherosclerosis Society

    Atherosclerosis

  5. Lipoprotein raises the risk of cardiovascular disease in humans.

    “Far from being a benign variant, it acts as a significant amplifier of cardiovascular risk”

    Review

    The burden of Lipoprotein(a) [Lp(a)] in Africa: A systematic review

    PloS one

  6. Lipoprotein raises the risk of cardiovascular disease in humans.

    “Lipoprotein(a) has emerged as an important genetically determined cardiovascular risk factor”

    Review

    Lipid-lowering therapy in transition: implications of the ESC/EAS focused update

    Deutsche medizinische Wochenschrift (1946)

  7. Lipoprotein raises the risk of cardiovascular disease in humans.

    “lipoprotein(a) (Lp[a]) is an independent, causal, genetic risk factor for cardiovascular disease (CVD) that promotes the progression of high-risk, vulnerable atherosclerotic plaque phenotypes”

    Review

    Unraveling Emerging Data on Lipoprotein(a)-Driven Cardiovascular Disease via Multiomics: A Review

    Global heart

  8. Lipoprotein raises the risk of cardiovascular disease in humans (elevated Lp(a)).

    “Observational studies demonstrate markedly increased cardiovascular risk with elevated Lp(a)”

    Reviewelevated Lp(a)

    The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice

    Reviews in cardiovascular medicine

  9. Lipoprotein raises the risk of cardiovascular disease in familial hypercholesterolemia.

    “mounting clinical evidence indicates that lowering LDL-C pharmacologically will not offset the specific cardiovascular risk stemming from elevated Lp(a) in FH.”

    Reviewin familial hypercholesterolemia

    Lipoprotein(a) in familial hypercholesterolemia

    Current opinion in lipidology

  10. Lipoprotein raises the risk of cardiovascular disease in humans.

    “Lipoprotein(a) [Lp(a)] is a well recognised contributor in the development of cardiovascular disease.”

    Review

    Lipoprotein(a): the neglected risk factor in cardiovascular health

    Frontiers in cardiovascular medicine

All 11

More on Cardiovascular disease

Major adverse cardiovascular events

upin humans10no changein humans1HR 1.06–2.6

10 studies
  1. Lipoprotein is associated with major adverse cardiovascular events in humans (LDL-C <70 mg/dL on statin and/or ezetimibe therapy) (HR 1.08; 95% CI 1.04–1.12).

    “patients with elevated Lp(a) had higher rates of MACE (HR 1.08; 95% CI 1.04-1.12; P<.001)”

    HumansLDL-C <70 mg/dL on statin and/or ezetimibe therapyLp(a) ≥50 mg/dL or ≥125 nmol/LMedian follow-up of 2.6 to 3.1 years42.3% femalesn = 41,750

    Lipoprotein(a) and Residual Vascular Risk Among Patients Achieving Optimal LDL-C: A Real-World Cohort Analysis

    AHA Scientific Sessions 2026 abstract

  2. Lipoprotein is associated with major adverse cardiovascular events in humans (Stable CAD; LDL-C ≥70 mg/dL; Lp(a) ≥50 versus <50 mg/dL) (Adjusted sHR 1.29, 95% CI 1.09–1.52; p=0.004).

    “elevated Lp(a) was independently associated with MACE in those with LDL-C ≥70 mg/dL”

    HumansStable CAD; LDL-C ≥70 mg/dL; Lp(a) ≥50 versus <50 mg/dL5 yearsn = 3,546

    Effect of LDL Cholesterol Level on Lipoprotein(a)-Associated Cardiovascular Risk in Stable Coronary Heart Disease

    AHA Scientific Sessions 2026 abstract

  3. Lipoprotein is associated with major adverse cardiovascular events in humans.

    “When adjusted for both diabetes and smoking Lp(a) also remained a significant predictor of MACE”

    HumansRecent acute coronary syndrome; placebo group on optimized statin therapy; adjusted for smoking and diabetesMedian follow-up 2.8 yearsn = 9,462

    Lipoprotein(a), smoking, and diabetes are additive, but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome: An analysis of the ODYSSEY OUTCOMES trial

    ESC Congress 2026 abstract

  4. Lipoprotein is associated with major adverse cardiovascular events in humans (Patients undergoing percutaneous coronary intervention) (Adjusted HR per 1 SD 1.07, 95% CI 1.02–1.12).

    “Over five years, higher Lp(a) was independently associated with an increased risk of MACE”

    HumansPatients undergoing percutaneous coronary intervention5 yearsn = 5,942

    Bridging the gap: real-world eligibility for lipoprotein(a)-targeted therapies in chronic and acute coronary syndrome

    ESC Congress 2026 abstract

  5. Lipoprotein is associated with major adverse cardiovascular events in humans (Secondary prevention subgroup; no significant predictive association).

    “in men Lp(a) predicted MACE only in primary prevention subgroups (per-SD HR 1.11-1.15; p < 0.001) but not in secondary prevention (p = 0.65).”

    HumansSecondary prevention subgroup; no significant predictive associationMedian follow-up 15.2 yearsmales

    Inflammation and lipoprotein(a) as predictors of cardiovascular events across baseline risk levels - results from the UK Biobank

    Atherosclerosis

  6. Lipoprotein predicts major adverse cardiovascular events in humans Across baseline cardiovascular risk subgroups (Per-SD HR 1.06–1.11 across subgroups).

    “Lp(a) predicted MACE independently but heterogeneously: in women associations were consistent across subgroups (per-SD HR 1.06-1.11; p ≤ 0.005)”

    HumansAcross baseline cardiovascular risk subgroupsMedian follow-up 15.2 yearsfemales

    Inflammation and lipoprotein(a) as predictors of cardiovascular events across baseline risk levels - results from the UK Biobank

    Atherosclerosis

  7. Lipoprotein is associated with major adverse cardiovascular events in humans (Patients undergoing percutaneous coronary intervention) (Adjusted HR per 1 SD 1.06, 95% CI 1.01–1.12).

    “higher Lp(a) was independently associated with risk of MACE (adjusted hazard ratio [HR] per 1 SD 1.06 [95% CI 1.01-1.12]; P = .015)”

    HumansPatients undergoing percutaneous coronary intervention5 yearsn = 5,942

    Real-world threshold-based eligibility for emerging lipoprotein(a)-targeted therapies in chronic and acute coronary syndrome

    Journal of clinical lipidology

  8. Lipoprotein is linked with a higher risk of major adverse cardiovascular events in humans across high-risk groups in general population.

    “MACE rates varied by group and increased progressively with higher Lp(a) thresholds.”

    Humansacross high-risk groups in general population

    Lipoprotein(a) distributions and trial eligibility thresholds for Lp(a)-lowering therapies in the general population: The Rotterdam Study

    European journal of preventive cardiology

  9. Lipoprotein is linked with a higher risk of major adverse cardiovascular events in humans (overall cohort).

    “elevated Lp(a) was associated with MACE in the overall cohort”

    Humansoverall cohortmedian 15.7 yearsn = 337,164

    Lipoprotein(a) and Cardiovascular-Kidney-Metabolic Syndrome: Stage-Specific Associations With All-Cause Mortality and Major Adverse Cardiovascular Events in the UK Biobank

    Research SquarePreprint

  10. Lipoprotein predicts major adverse cardiovascular events in humans (Symptomatic, advanced coronary artery calcification; lipoprotein(a) ≥50 versus <50 mg/dL) (37.7% vs. 15.8%; adjusted HR 2.60, 95% CI 1.55–4.35).

    “the elevated Lp(a) cohort had a significantly higher MACE rate (37.7% vs. 15.8%; adjusted hazard ratio [aHR] 2.60, 95% CI 1.55-4.35, p < 0.001).”

    HumansSymptomatic, advanced coronary artery calcification; lipoprotein(a) ≥50 versus <50 mg/dLMedian follow-up of 17.2 monthsn = 292

    Elevated lipoprotein(a) and adverse outcomes in advanced coronary artery calcification: An intravascular ultrasound study

    International journal of cardiology. Cardiovascular risk and prevention

All 11

Calcific aortic valve stenosis

upin humans7upin reviews2

9 studies
  1. Lipoprotein raises the risk of calcific aortic valve stenosis in humans.

    “and it is also causally implicated in calcific aortic valve stenosis.”

    Review

    Lipoprotein(a) in the statin era: from risk marker to therapeutic target

    Frontiers in pharmacology

  2. Lipoprotein raises the risk of calcific aortic valve stenosis in humans (elevated concentrations (particularly ≥ 125 nmol/L)).

    “individuals with elevated concentrations (particularly ≥ 125 nmol/L) face substantial incremental ASCVD and CAVS risk.”

    Reviewelevated concentrations (particularly ≥ 125 nmol/L)

    Lipoprotein(a) in Japan: An Expert Consensus Statement

    Journal of atherosclerosis and thrombosis

  3. Lipoprotein raises the risk of calcific aortic valve stenosis.

    “causal, independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis”

    Review

    Lipoprotein(a) measurement: challenges and opportunities

    Clinical chemistry and laboratory medicine

  4. Lipoprotein raises the risk of calcific aortic valve stenosis in humans (genetically determined).

    “independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS)”

    Reviewgenetically determined

    Lipoprotein(a) in Personalized Cardiovascular Prevention: Risk Stratification, Coronary Artery Calcium, and Emerging Lp(a)-Lowering Therapies

    Journal of clinical medicine

  5. Lipoprotein raises the risk of calcific aortic valve stenosis in humans (elevated Lp(a)).

    “Lipoprotein(a) [Lp(a)] is a causal, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS).”

    Reviewelevated Lp(a)

    Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target

    Cells

  6. Lipoprotein raises the risk of calcific aortic valve stenosis in humans (genetically determined).

    “independent risk factor for atherosclerotic cardiovascular disease, including acute coronary syndrome, peripheral arterial disease, and stroke, as well as calcific aortic stenosis”

    Reviewgenetically determined

    Clinical Care for Patients With Elevated Lipoprotein(a) Level in Canada: A Practical Framework for Screening, Risk Assessment, and Management

    The Canadian journal of cardiology

  7. Lipoprotein raises the risk of calcific aortic valve stenosis in humans (genetically determined).

    “Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS)”

    Reviewgenetically determined

    A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions

    Korean circulation journal

  8. Lipoprotein is associated with calcific aortic valve stenosis.

    “Lp(a) is strongly associated with calcific aortic valve stenosis (CAVS), coronary artery disease (CAD), peripheral arterial disease (PAD)”

    Review

    Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective

    Atherosclerosis

  9. Lipoprotein predicts calcific aortic valve stenosis in humans.

    “Elevated plasma lipoprotein(a) and oxidized phospholipids predict progression of pre-existing aortic stenosis and need for aortic valve replacement.”

    Review

    Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis

    Current opinion in cardiology

More on Calcific aortic valve stenosis

Mortality

upin humans8HR 1.13–1.58

8 studies
  1. Lipoprotein is associated with mortality in humans (Baseline coronary artery disease).

    “Restricted cubic spline analysis demonstrated a positive dose-response relationship between Lp(a) levels and the risks of cardiovascular and all-cause mortality.”

    HumansBaseline coronary artery diseaseMedian follow-up of 5.2 years23.5% femalesn = 51,489

    Association of Lipoprotein(a) with cardiovascular and all-cause mortality in China: a cohort study based on cardiorenal improvementNT-II

    ESC Congress 2026 abstract

  2. Lipoprotein is linked with a higher risk of mortality in humans (CKM stage 3) (HR 1.13, 95% CI 1.01–1.25).

    “high Lp(a) was associated with a modestly higher risk in CKM stage 3 (HR, 1.13; 95% CI, 1.01–1.25; P = 0.03)”

    HumansCKM stage 3median 15.7 yearsn = 337,164

    Lipoprotein(a) and Cardiovascular-Kidney-Metabolic Syndrome: Stage-Specific Associations With All-Cause Mortality and Major Adverse Cardiovascular Events in the UK Biobank

    Research SquarePreprint

  3. Lipoprotein is linked with a higher risk of mortality in humans (acute decompensated heart failure) (adjusted HR 1.21 (95% CI 1.05-1.39)).

    “In all patients, log-transformed Lp(a) was significantly associated with mortality (adjusted HR 1.21; 95% CI, 1.05-1.39; P = 0.007)”

    Humansacute decompensated heart failure4.1 years (median)n = 2,610

    Impact of hypertension on associations of all-cause mortality with admission lipoprotein (a) in acute decompensated heart failure

    International journal of cardiology. Cardiovascular risk and prevention

  4. Lipoprotein is associated with mortality in high baseline CV risk group (HR 1.25, 95% CI 1.02-1.53).

    “In the high-risk group, Lp(a) >75 mg/dL was associated with higher all-cause (HR: 1.25; 95% CI: 1.02-1.53)”

    Humansin high baseline CV risk group>75 mg/dL

    The Additive Prognostic Value of Lipoprotein(a) for All-cause and Cardiovascular Mortality Across the Traditional Cardiovascular Risk Continuum: Analysis from NHANES III (1988-1994) with Follow-Up to 2019

    European journal of preventive cardiology

  5. Lipoprotein is linked with a higher risk of mortality in humans (primary prevention, >95th percentile (>100 mg/dL) vs <50th percentile) (adjusted HR: 1.37; 95%CI: 1.07–1.75).

    “only those with Lp(a) >95th percentile (>100 mg/dL) showed a significantly higher risk of ACM (adjusted HR: 1.37; 95%CI: 1.07–1.75; p=0.012”

    Humansprimary prevention, >95th percentile (>100 mg/dL) vs <50th percentileup to 15 years54% malessn = 42,770

    Reevaluating Lipoprotein(a) Levels and Risk of All-Cause Mortality in the Setting of Primary Prevention: A Retrospective Cohort Study

    AHA Scientific Sessions 2025 abstract

  6. Lipoprotein is associated with mortality in humans (EPIC-Norfolk participants) (HR 1.17, 95% CI 1.08–1.27).

    “those with Lp(a) levels ≥50 mg/dL had an increased hazard ratio (HR) for all-cause (HR=1.17, 95% CI=1.08-1.27)”

    HumansEPIC-Norfolk participantsLp(a) ≥50 mg/dL versus <50 mg/dL20 yearsn = 18,720

    Long-Term Exposure to Elevated Lipoprotein(a) Levels, Parental Lifespan and Risk of Mortality

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

  7. Lipoprotein is associated with mortality in humans After bioprosthetic aortic valve replacement; elevated versus lower serum lipoprotein(a) (HR 1.53, 95% CI 1.13–2.08).

    “Elevated Lp(a) was associated with significantly increased risks of SVD and all-cause mortality following bioprosthetic aortic valve replacement.”

    ReviewAfter bioprosthetic aortic valve replacement; elevated versus lower serum lipoprotein(a)

    Elevated Lipoprotein(a) and Bioprosthetic Valve Outcomes: A Sytematic Review and Meta-Analysis

    AHA Scientific Sessions 2026 abstract

  8. Lipoprotein is associated with mortality in humans (maintenance dialysis patients; exploratory meta-analysis) (HR 1.58, 95% CI 1.24–2.02).

    “Exploratory meta-analyses revealed associations between elevated Lp(a) levels and all-cause mortality (HR: 1.58; 95% CI: 1.24-2.02)”

    Reviewmaintenance dialysis patients; exploratory meta-analysis

    Lipoprotein(a) and adverse cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis

    Lipids in health and disease

Myocardial infarction

upin humans7upin reviews1HR 1.09–2.61

8 studies
  1. Lipoprotein is associated with myocardial infarction in humans (Elevated lipoprotein(a) >50 mg/dL; adjusted for traditional cardiovascular risk factors) (HR 1.44, 95% CI 1.42–1.46).

    “followed by MI (HR 1.44, 95% CI 1.42-1.46), PAD (HR 1.31, 95% CI 1.28-1.33), and stroke (HR 1.15, 95% CI 1.13-1.16).”

    HumansElevated lipoprotein(a) >50 mg/dL; adjusted for traditional cardiovascular risk factors

    Elevated Lipoprotein(a) and Initial Cardiovascular Disease Presentation: Disease-Specific Associations and Age Interactions in a National Cohort

    AHA Scientific Sessions 2026 abstract

  2. Lipoprotein is linked with a higher risk of myocardial infarction in humans (OR 1.78, 95% CI 1.31-2.41).

    “previous MI (OR 1.78, 95% CI 1.31-2.41)”

    Humansn = 23,654

    Distribution of lipoprotein(a) and its association with atherosclerotic cardiovascular disease in a large real-world Polish cohort

    Journal of clinical lipidology

  3. Lipoprotein is linked with a higher risk of myocardial infarction in humans (elevated Lp(a) >= 125 nmol/L) (2.6% vs 2.0%; HR 1.20, 95% CI 1.00-1.43).

    “and myocardial infarction (2.6% vs 2.0%; HR 1.20, 95% CI 1.00-1.43; P = 0.047)”

    Humanselevated Lp(a) >= 125 nmol/L

    Integrating Lipoprotein(a) with Retinal Imaging Biomarkers for Cardiovascular Risk Assessment: UK Biobank Analysis

    ADA Scientific Sessions 2026 abstract

  4. Lipoprotein is linked with a higher risk of myocardial infarction in humans (very high Lp(a) (>230 nmol/L) vs low Lp(a) (≤7 nmol/L)) (P = 0.012).

    “Individuals with very high Lp(a) had significantly lower event-free survival time for the diagnosis of obstructive CAD and occurrence of MI (P = 0.006 and P = 0.012, respectively).”

    Humansvery high Lp(a) (>230 nmol/L) vs low Lp(a) (≤7 nmol/L)

    Lipoprotein(a) and the Early Diagnosis, Complexity, and Extent of Coronary Artery Disease and Myocardial Infarction

    JACC. Advances

  5. Lipoprotein is linked with a higher risk of myocardial infarction in humans (top vs bottom quintile, adjusted for CV risk factors and other two biomarkers) (HR 1.09 (95% CI: 1.08–1.11)).

    “Adjusted HRs for MI comparing the top versus bottom quintiles were 1.09 (95% CI: 1.08–1.11) for Lp(a)”

    Humanstop vs bottom quintile, adjusted for CV risk factors and other two biomarkers15-year median follow-upn = 306,183

    Additive Value of Lipoprotein(a), Remnant Cholesterol, and Inflammation for Risk Stratification of Myocardial Infarction: Evidence from the UK Biobank

    AHA Scientific Sessions 2025 abstract

  6. Lipoprotein is linked with a higher risk of myocardial infarction in humans (no baseline atherosclerotic cardiovascular disease) (adjusted HR, 2.61 (95% CI, 1.48-4.61)).

    “strongest association was present between lipoprotein(a) and fatal or nonfatal myocardial infarction (women: adjusted HR, 2.61 [95% CI, 1.48-4.61]”

    Humansno baseline atherosclerotic cardiovascular diseasefemales

    Sex Differences in the Association Between Lipoprotein(a) and Cardiovascular Outcomes: The MGB Lp(a) Registry

    Journal of the American Heart Association

  7. Lipoprotein is associated with myocardial infarction.

    “it carries a well-established association with myocardial infarction, stroke, and aortic stenosis”

    Review

    Residual cardiovascular risk beyond LDL-cholesterol control: what remains unaddressed?

    American journal of cardiovascular disease

  8. Myocardial infarction is associated with lipoprotein in humans.

    “younger are more likely to be men, have familial-combined hyperlipidaemia and increased levels of lipoprotein-a.”

    Review

    Risk factors profile of young and older patients with myocardial infarction

    Cardiovascular research

More on Myocardial infarction

Aortic valve stenosis

upin humans7HR 1.39–1.6

7 studies
  1. Lipoprotein is linked with a higher risk of aortic valve stenosis in humans (CVD-free participants; one-sample Mendelian randomization) (HR per SD 1.12, 95% CI 1.03–1.23).

    “The instrument predicted both outcomes (HR per SD genetically predicted Lp(a) 1.05 [95%CI 1.02-1.08] for ASCVD; 1.12 [1.03-1.23] for AVS)”

    HumansCVD-free participants; one-sample Mendelian randomizationper SD genetically predicted Lp(a)n = 28,949

    Genetic analysis links a blood fat particle to 60 proteins

    AHA Scientific Sessions 2026 abstract

  2. Lipoprotein is associated with aortic valve stenosis in humans (Elevated lipoprotein(a) >50 mg/dL; adjusted for traditional cardiovascular risk factors) (HR 1.60, 95% CI 1.55–1.64).

    “Elevated Lp(a) had the strongest association with AS risk (HR 1.60, 95% CI 1.55-1.64)”

    HumansElevated lipoprotein(a) >50 mg/dL; adjusted for traditional cardiovascular risk factors

    Elevated Lipoprotein(a) and Initial Cardiovascular Disease Presentation: Disease-Specific Associations and Age Interactions in a National Cohort

    AHA Scientific Sessions 2026 abstract

  3. Lipoprotein is associated with aortic valve stenosis in humans (HR 1.39 with LDL-C <55 mg/dL; HR 1.35 with LDL-C <70 mg/dL).

    “In both LDL-C strata, higher Lp(a) was associated with significantly greater residual risk of recurrent MI, ischemic stroke, peripheral artery disease, and aortic stenosis.”

    HumansPrior myocardial infarction and LDL-C <55 mg/dL; higher versus lower lipoprotein(a), using a threshold of 125 nmol/L or 50 mg/dL; 3,827 patients per groupn = 3,827

    Higher Lipoprotein(a) Identifies Residual Cardiovascular Risk Despite Achieving LDL-C Targets After Myocardial Infarction

    AHA Scientific Sessions 2026 abstract

  4. Lipoprotein raises the risk of aortic valve stenosis in humans.

    “independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis.”

    Review

    Lipoprotein(a): Actionable today, treatable tomorrow?

    Australian journal of general practice

  5. Lipoprotein raises the risk of aortic valve stenosis in humans.

    “Epidemiological and Mendelian randomisation studies consistently demonstrate a strong and likely causal association between elevated lipoprotein(a) and AS.”

    Review

    Lipoprotein(a) and Aortic Stenosis: From Genetic Risk to Emerging Therapeutic Strategies

    European cardiology

  6. Lipoprotein raises the risk of aortic valve stenosis in humans (elevated levels).

    “Lipoprotein(a) [Lp(a)] is a risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis.”

    Reviewelevated levels

    Lipoprotein(a) - the hereditary risk factor for cardiovascular disease

    Lakartidningen

  7. Lipoprotein raises the risk of aortic valve stenosis in humans.

    “Lipoprotein(a) [Lp(a)] constitutes an independent, causal risk factor for ASCVD and aortic valve stenosis.”

    Review

    Incorporating lipoprotein(a) into patient care: the Polish landscape in light of national recommendations and the updated ESC/EAS guidelines

    Archives of medical science : AMS

More on Aortic valve stenosis

Calcific aortic valve disease

upin humans5

5 studies
  1. Lipoprotein is linked with a higher risk of calcific aortic valve disease in humans (> 30 mg/dL vs ≤ 30 mg/dL) (2–4 fold).

    “The prevalence of CAVD in non-elderly populations was markedly 2–4 fold greater in the higher Lp(a) group (> 30 mg/dL) than in the lower Lp(a) group (≤ 30 mg/dL).”

    Humans> 30 mg/dL vs ≤ 30 mg/dL> 30 mg/dL

    Decoding calcific aortic valve disease: superior predictive power of time-weighted lipoprotein(a)

    Lipids in health and disease

  2. Calcific aortic valve disease is associated with lipoprotein in humans (> 2-fold).

    “The average Lp(a) level in the young populations with CAVD was more than twice that in the No-CAVD group, particularly among those aged 55 years or younger.”

    Humans

    Decoding calcific aortic valve disease: superior predictive power of time-weighted lipoprotein(a)

    Lipids in health and disease

  3. Lipoprotein raises the risk of calcific aortic valve disease in humans (elevated Lp(a)).

    “Genetic, epidemiological, and mechanistic evidence supports a causal role for elevated Lp(a) in atherosclerotic cardiovascular disease and calcific aortic valve disease.”

    Reviewelevated Lp(a)

    Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions

    Reviews in cardiovascular medicine

  4. Lipoprotein raises the risk of calcific aortic valve disease in humans (elevated plasma levels).

    “Elevated plasma lipoprotein(a) [Lp(a)] levels represent a predominantly genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease (CAVD).”

    Reviewelevated plasma levels

    Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved

    International journal of molecular sciences

  5. Lipoprotein raises the risk of calcific aortic valve disease in humans.

    “has been established as an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD)”

    Review

    2026 Consensus and review of Lipoprotein(a) from Taiwan Society of Lipid and Atherosclerosis: Molecular pathogenesis, epidemiology, clinical implications, and advances in diagnostic strategies

    Journal of the Formosan Medical Association = Taiwan yi zhi

  6. Lipoprotein raises the risk of calcific aortic valve disease in humans.

    “Elevated levels of lipoprotein(a) [Lp(a)] have been identified as an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and, more recently, calcific aortic valve disease (CAVD).”

    Review

    Lipoprotein(a): Expanding our knowledge of aortic valve narrowing

    Trends in cardiovascular medicine

More on Calcific aortic valve disease

Ischemic stroke

upin humans4upin reviews1OR 1.01–1.44

5 studies
  1. Lipoprotein is associated with ischemic stroke in humans (OR 1.44, 95% CI 1.25-1.66).

    “Among Black individuals, elevated Lp(a) was associated with increased odds of stroke (OR 1.44, 95% CI 1.25-1.66)”

    HumansBlack individuals; high (≥100 mg/dL or ≥250 nmol/L) versus low (<30 mg/dL or <75 nmol/L) lipoprotein(a)

    Cardiovascular Risk Associated with High vs Low Lipoprotein(a) Across Black and White Individuals

    AHA Scientific Sessions 2026 abstract

  2. Lipoprotein is associated with ischemic stroke in humans (HR 1.34 with LDL-C <55 mg/dL; HR 1.33 with LDL-C <70 mg/dL).

    “In both LDL-C strata, higher Lp(a) was associated with significantly greater residual risk of recurrent MI, ischemic stroke, peripheral artery disease, and aortic stenosis.”

    HumansPrior myocardial infarction and LDL-C <55 mg/dL; higher versus lower lipoprotein(a), using a threshold of 125 nmol/L or 50 mg/dL; 3,827 patients per groupn = 3,827

    Higher Lipoprotein(a) Identifies Residual Cardiovascular Risk Despite Achieving LDL-C Targets After Myocardial Infarction

    AHA Scientific Sessions 2026 abstract

  3. Lipoprotein predicts ischemic stroke in humans (Symptomatic, advanced coronary artery calcification; lipoprotein(a) ≥50 versus <50 mg/dL) (Adjusted HR 7.14).

    “Elevated Lp(a) independently predicted increased risks of ischemic stroke (aHR 7.14) and in-stent restenosis (aHR 2.78).”

    HumansSymptomatic, advanced coronary artery calcification; lipoprotein(a) ≥50 versus <50 mg/dLMedian follow-up of 17.2 monthsn = 292

    Elevated lipoprotein(a) and adverse outcomes in advanced coronary artery calcification: An intravascular ultrasound study

    International journal of cardiology. Cardiovascular risk and prevention

  4. Lipoprotein is linked with a higher risk of ischemic stroke in humans (per 100 nmol/L increase in genetically predicted Lp(a) levels) (OR 1.04 (95% CI, 1.02-1.07), P=2.05×10−4).

    “Genetically predicted Lp(a) levels associated with significantly increased risk of all-cause ischemic stroke (odds ratio [OR], 1.04 [95% CI, 1.02-1.07], P=2.05×10−4)”

    Humansper 100 nmol/L increase in genetically predicted Lp(a) levels

    Genetically Predicted Levels of Lipoprotein(a) and Risk of Cerebrovascular Disease

    Journal of the American Heart Association

  5. Lipoprotein is associated with ischemic stroke (OR 1.01, 95% CI 0.99-1.02; not statistically significant).

    “the association between Lp(a) and IS was not statistically significant (OR 1.01, 95% CI 0.99-1.02; p = 0.26, I 2 = 57%)”

    Review

    Associations between lipoproteins and risk of ischemic stroke: a systematic review and meta-analysis of Mendelian randomization studies

    Frontiers in neurology

More on Ischemic stroke

Race and ethnicity

mixedin humans1

1 study
  1. race and ethnicity is associated with lipoprotein in humans (baseline values before treatment) (median baseline 108.6 nmol/L in Black or African American participants vs 36.1 nmol/L in White participants).

    “baseline Lp(a) levels varied by race”

    Human trialbaseline values before treatmentn = 3,187

    An oral drug lowers lipoprotein(a) across patient groups

    ESC Congress 2026 abstract

Oxidized phospholipids on apolipoprotein

downin humans1

1 study
  1. Oxidized phospholipids on apolipoprotein is associated with lipoprotein in humans (percent change in Lp(a) during lepodisiran treatment).

    “Percent change in OxPL-apo(a) correlated more closely than OxPL-apoB with percent change in Lp(a) than did OxPL-apoB.”

    Human trialpercent change in Lp(a) during lepodisiran treatment

    Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a)

    Journal of the American College of Cardiology

More on Oxidized phospholipids on apolipoprotein

All 222

Funding

41 grants since 2016

National Heart, Lung, and Blood Institute$12MNational Eye Institute$5.2MNational Institute on Aging$5.5M

Latest

See all 6,010 papers on lipoprotein